AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Stifel Financial Corp

Stifel Financial Corp raised its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 6.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,348,904 shares of the company's stock after purchasing an additional 83,486 shares during the quarter. Stifel Financial Corp's holdings in AstraZeneca were worth $105,093,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Tidal Investments LLC acquired a new position in AstraZeneca during the first quarter worth $327,000. CWM LLC grew its holdings in AstraZeneca by 35.4% during the second quarter. CWM LLC now owns 11,843 shares of the company's stock worth $924,000 after acquiring an additional 3,094 shares during the period. Csenge Advisory Group acquired a new position in AstraZeneca during the second quarter worth $234,000. U.S. Capital Wealth Advisors LLC grew its holdings in AstraZeneca by 4.7% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 4,832 shares of the company's stock worth $377,000 after acquiring an additional 219 shares during the period. Finally, Capital Investment Advisors LLC acquired a new position in AstraZeneca during the second quarter worth $222,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. UBS Group upgraded AstraZeneca from a "sell" rating to a "neutral" rating in a research report on Wednesday, November 20th. Finally, Erste Group Bank upgraded AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN traded up $0.67 on Friday, hitting $68.20. The company had a trading volume of 6,813,708 shares, compared to its average volume of 5,311,993. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The business has a 50 day moving average of $71.46 and a 200 day moving average of $77.17. The company has a market cap of $211.46 billion, a PE ratio of 32.62, a PEG ratio of 1.22 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the business posted $0.87 earnings per share. The firm's revenue for the quarter was up 18.0% compared to the same quarter last year. As a group, equities analysts anticipate that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.